Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akili, Inc.DNAA · Entity 89130 | Director | June 29, 2021 | June 29, 2021 |
| Biohaven Ltd.BHVN · Entity 4379 | Director · Chief Executive Officer | February 27, 2026 | March 03, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | Director · Chief Executive Officer | October 03, 2022 | October 03, 2022 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | June 05, 2026 | June 08, 2026 |
| Veradermics, IncMANE · Entity 1907 | Director | February 03, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akili, Inc.
Report date June 29, 2021 · Filed June 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-06-29 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.
Biohaven Ltd.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.52 · Expires 2036-02-27 | Direct | 550,000 |
Reported balance
After 2026-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-27 · Grant · Acquired 550,000 · Balance 550,000 F1: The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 830,891 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 92,050 · Balance 830,891 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Common SharesSEC Table I · non-derivative | IndirectBy: The Vladimir Coric Marital Trust | 517,391 |
Reported balance
After 2022-10-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-10-03 · Disposition to issuer · Disposed 313,500 · Balance 517,391 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Common SharesSEC Table I · non-derivative | IndirectBy 401(K) Plan | 498,261 |
Reported balance
After 2022-10-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2022-10-03 · Disposition to issuer · Disposed 19,130 · Balance 498,261 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Common SharesSEC Table I · non-derivative | IndirectBy: The Vladimir Coric Family Trust | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 498,261 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-03 · Disposition to issuer · Disposed 13,336 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-03 · Disposition to issuer · Disposed 13,336 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-03 · Disposition to issuer · Disposed 4,444 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-10-03 · Disposition to issuer · Disposed 4,444 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-10-03 · Disposition to issuer · Disposed 4,444 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-10-03 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-10-03 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-10-03 · Disposition to issuer · Disposed 10,950 · Balance 0 F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.69 · Expires 2032-01-07 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-10-03 · Disposition to issuer · Disposed 775 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.69 · Expires 2032-01-07 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-10-03 · Disposition to issuer · Disposed 69,225 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.32 · Expires 2031-01-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2022-10-03 · Disposition to issuer · Disposed 2,398 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.32 · Expires 2031-01-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2022-10-03 · Disposition to issuer · Disposed 97,602 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.99 · Expires 2029-11-25 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2022-10-03 · Disposition to issuer · Disposed 87,500 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2022-10-03 · Disposition to issuer · Disposed 196,916 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2022-10-03 · Disposition to issuer · Disposed 3,084 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.28 · Expires 2027-12-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2022-10-03 · Disposition to issuer · Disposed 19,240 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.28 · Expires 2027-12-06 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2022-10-03 · Disposition to issuer · Disposed 180,760 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2027-04-05 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2022-10-03 · Disposition to issuer · Disposed 40,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.07 · Expires 2026-12-14 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2022-10-03 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.47 · Expires 2025-10-22 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2022-10-03 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.47 · Expires 2025-10-22 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2022-10-03 · Disposition to issuer · Disposed 75,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2024-11-25 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2022-10-03 · Disposition to issuer · Disposed 250,000 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Royalty Pharma plc
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 15,343 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 4,545 · Balance 15,343 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
Veradermics, Inc
Report date February 03, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 33,706 |
Reported balance
After 2026-02-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-02-05 · Conversion · Acquired 33,706 · Balance 33,706 F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Shares held by Vladimir Coric Family Trust 2013. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 33,706 |
Reported balance
After 2026-02-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-05 · Conversion · Acquired 33,706 · Balance 33,706 F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Shares held by Vladimir Coric Marital Trust 2013. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 182,500 |
Reported balance
After 2026-02-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-02-05 · Conversion · Acquired 148,794 · Balance 182,500 F4: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Shares held by Vladimir Coric Family Trust 2013. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 182,500 |
Reported balance
After 2026-02-05 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-02-05 · Conversion · Acquired 148,794 · Balance 182,500 F4: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Shares held by Vladimir Coric Marital Trust 2013. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 260,575 |
Reported balance
After 2026-02-05 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-02-05 · Conversion · Acquired 78,075 · Balance 260,575 F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Shares held by Vladimir Coric Family Trust 2013. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 260,575 |
Reported balance
After 2026-02-05 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2026-02-05 · Conversion · Acquired 78,075 · Balance 260,575 F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Shares held by Vladimir Coric Marital Trust 2013. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 319,398 |
Reported balance
After 2026-02-05 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2026-02-05 · Purchase · Acquired 58,823 · Balance 319,398 F2: Shares held by Vladimir Coric Family Trust 2013. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 319,398 |
Reported balance
After 2026-02-05 transaction · row 9
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 9 · 2026-02-05 · Purchase · Acquired 58,823 · Balance 319,398 F3: Shares held by Vladimir Coric Marital Trust 2013. |
| Common StockSEC Table I · non-derivative | Direct | 129,939 |
Reported balance
After 2026-02-05 transaction · row 7
1 source rowRow 7 · 2026-02-05 · Conversion · Acquired 117,112 · Balance 129,939 F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-05 · Conversion · Disposed 33,706 · Balance 0 F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Shares held by Vladimir Coric Family Trust 2013. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-05 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-02-05 · Conversion · Disposed 33,706 · Balance 0 F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Shares held by Vladimir Coric Marital Trust 2013. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-05 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-02-05 · Conversion · Disposed 148,794 · Balance 0 F4: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Shares held by Vladimir Coric Family Trust 2013. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-05 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-02-05 · Conversion · Disposed 148,794 · Balance 0 F4: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Shares held by Vladimir Coric Marital Trust 2013. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-05 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-02-05 · Conversion · Disposed 78,075 · Balance 0 F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: Shares held by Vladimir Coric Family Trust 2013. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-05 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-02-05 · Conversion · Disposed 78,075 · Balance 0 F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3: Shares held by Vladimir Coric Marital Trust 2013. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-05 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-02-05 · Conversion · Disposed 117,112 · Balance 0 F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-02-03 | Direct | 51,525 |
Reported balance
After 2026-02-03 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-02-03 · Grant · Acquired 51,525 · Balance 51,525 F6: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
F2: Shares held by Vladimir Coric Family Trust 2013.
F3: Shares held by Vladimir Coric Marital Trust 2013.
F4: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
F5: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
F6: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Revance Therapeutics, Inc.
Report date February 04, 2025 · Filed February 06, 2025
Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-04 · Other · Disposed 5,784 · Balance 15,000 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 2 · 2025-02-06 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.
F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 20:21 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 4,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001704317-26-000006 · wk-form4_1780950084.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,343 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:04 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 550,000 | $0.00 Strike: $11.52 | $0.00 |
DisclosureSEC source: 0001704317-26-000004 · wk-form4_1772579067.xml · derivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Shares · 550,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries C Convertible Preferred Stock · Derivative | 117,112 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · derivative · entry 16 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 117,112 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · derivative.exercise_date: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · derivative.expiration_date: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries C Convertible Preferred Stock · Derivative | 78,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · derivative · entry 15 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 78,075 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · derivative.exercise_date: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · derivative.expiration_date: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Shares held by Vladimir Coric Marital Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries C Convertible Preferred Stock · Derivative | 78,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · derivative · entry 14 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 78,075 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · derivative.exercise_date: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · derivative.expiration_date: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by Vladimir Coric Family Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries B Convertible Preferred Stock · Derivative | 148,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · derivative · entry 13 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 148,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Shares held by Vladimir Coric Marital Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries B Convertible Preferred Stock · Derivative | 148,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · derivative · entry 12 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 148,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by Vladimir Coric Family Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries A Convertible Preferred Stock · Derivative | 33,706 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · derivative · entry 11 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 33,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Shares held by Vladimir Coric Marital Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries A Convertible Preferred Stock · Derivative | 33,706 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · derivative · entry 10 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 33,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by Vladimir Coric Family Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon Stock | 58,823 | $17.00 | $999,991.00 |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · nonDerivative · entry 9 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 319,398 F3 · ownership.nature: Shares held by Vladimir Coric Marital Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon Stock | 58,823 | $17.00 | $999,991.00 |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · nonDerivative · entry 8 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 319,398 F2 · ownership.nature: Shares held by Vladimir Coric Family Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 117,112 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · nonDerivative · entry 7 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 78,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · nonDerivative · entry 6 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 260,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Shares held by Vladimir Coric Marital Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 78,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · nonDerivative · entry 5 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 260,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by Vladimir Coric Family Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 148,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · nonDerivative · entry 4 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 182,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Shares held by Vladimir Coric Marital Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 148,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · nonDerivative · entry 3 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 182,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by Vladimir Coric Family Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 33,706 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 33,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Shares held by Vladimir Coric Marital Trust 2013. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 33,706 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 33,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: Shares held by Vladimir Coric Family Trust 2013. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:04 UTC | Veradermics, Inc MANE · Entity 1907 | GrantStock Option (Right to Buy) · Derivative | 51,525 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001628280-26-005907 · wk-form4_1770336262.xml · derivative · entry 17 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,525 Underlying: Common Stock · 51,525 shares Expires 2036-02-03 F6 · derivative.exercise_date: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 02:32 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionRestricted Share Unit Award · Derivative | 14,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001704317-26-000002 · wk-form4_1767839548.xml · derivative · entry 6 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Shares · 14,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted 57,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 02:32 UTC | Biohaven Ltd. BHVN · Entity 4379 | Tax withholdingCommon Shares | 7,430 | $9.93 | $73,779.90 |
DisclosureSEC source: 0001704317-26-000002 · wk-form4_1767839548.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,803,968 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 02:32 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 14,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001704317-26-000002 · wk-form4_1767839548.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,811,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 12:30 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 333,333 | $7.50 | $2,499,997.50 |
DisclosureSEC source: 0001704317-25-000004 · wk-form4_1763382609.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vladimir Coric Marital Trust Disclosed balance after: 740,546 F1 · shares: Represents common shares acquired in an underwritten public offering. F2 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 12:30 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 333,333 | $7.50 | $2,499,997.50 |
DisclosureSEC source: 0001704317-25-000004 · wk-form4_1763382609.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vlad Coric Family Trust Disclosed balance after: 1,195,275 F1 · shares: Represents common shares acquired in an underwritten public offering. F2 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 13, 2025 Filed May 14, 2025 21:06 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 7,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000047 · wk-form4_1747256775.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,798 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 21:43 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 3,184 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000023 · wk-form4_1745271779.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,184 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| February 06, 2025 Filed Feb 6, 2025 15:49 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Disposition to issuerCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-015343 · ownership.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 15:49 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 5,784 | $3.65 | $21,111.60 |
DisclosureSEC source: 0000950170-25-015343 · ownership.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:48 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionRestricted Share Unit Award · Derivative | 14,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000002 · wk-form4_1736300913.xml · derivative · entry 8 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,750 Underlying: Common Shares · 14,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F5 · derivative.exercise_date: The reporting person was granted 57,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F6 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:48 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantRestricted Share Unit Award · Derivative | 57,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000002 · wk-form4_1736300913.xml · derivative · entry 7 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Shares · 57,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F5 · derivative.exercise_date: The reporting person was granted 57,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F6 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:48 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 343,000 | $0.00 Strike: $38.64 | $0.00 |
DisclosureSEC source: 0001935979-25-000002 · wk-form4_1736300913.xml · derivative · entry 6 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,000 Underlying: Common Shares · 343,000 shares Expires 2035-01-05 F3 · derivative.exercise_date: The shares underlying this option vest in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:48 UTC | Biohaven Ltd. BHVN · Entity 4379 | Tax withholdingCommon Shares | 6,805 | $38.64 | $262,945.20 |
DisclosureSEC source: 0001935979-25-000002 · wk-form4_1736300913.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,796,604 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:48 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 14,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000002 · wk-form4_1736300913.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,803,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 11:00 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 21,052 | $47.50 | $999,970.00 |
DisclosureSEC source: 0001935979-24-000077 · wk-form4_1727953231.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vlad Coric Family Trust Disclosed balance after: 861,942 F1 · shares: Represents common shares acquired in an underwritten public offering. F2 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 01, 2024 Filed May 3, 2024 08:43 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 23,458 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001479290-24-000085 · wk-form4_1714740220.xml · derivative · entry 2 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,458 Underlying: Common Stock · 23,458 shares Expires 2034-04-30 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 01, 2024 Filed May 3, 2024 08:43 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-24-000085 · wk-form4_1714740220.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,784 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 11:54 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 121,951 | $41.00 | $4,999,991.00 |
DisclosureSEC source: 0001562180-24-003493 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,788,417 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:21 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantCommon Shares | 231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-003336 · primarydocument.xml · nonDerivative · entry 3 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vladimir Coric Marital Trust Disclosed balance after: 407,213 F1 · kind: Pursuant to merger transaction, consummated on January 8, 2024, 16,168 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 694 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to merger transaction, consummated on January 8, 2024, 16,168 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 694 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F2 · ownership.nature: These common shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:21 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantCommon Shares | 231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-003336 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vlad Coric Family Trust Disclosed balance after: 840,890 F1 · kind: Pursuant to merger transaction, consummated on January 8, 2024, 16,168 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 694 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to merger transaction, consummated on January 8, 2024, 16,168 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 694 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F2 · ownership.nature: These common shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:21 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantCommon Shares | 232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-003336 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,666,466 F1 · kind: Pursuant to merger transaction, consummated on January 8, 2024, 16,168 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 694 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to merger transaction, consummated on January 8, 2024, 16,168 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 694 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. Read SEC document |
| March 08, 2024 Filed Mar 8, 2024 23:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantCommon Shares | 2,155 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-002509 · primarydocument.xml · nonDerivative · entry 3 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vladimir Coric Marital Trust Disclosed balance after: 406,982 F1 · kind: Pursuant to an agreement and plan of merger, dated as of January 7, 2024, common shares of the Issuer were issued to the Reporting Person on March 8, 2024. The acquisition of the acquired company pursuant to the agreement and plan of merger and the issuance of common shares of the Issuer to the Reporting Person in connection therewith were approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to an agreement and plan of merger, dated as of January 7, 2024, common shares of the Issuer were issued to the Reporting Person on March 8, 2024. The acquisition of the acquired company pursuant to the agreement and plan of merger and the issuance of common shares of the Issuer to the Reporting Person in connection therewith were approved by the Board of the Issuer pursuant to Rule 16b-3. F3 · ownership.nature: These common shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2024 Filed Mar 8, 2024 23:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantCommon Shares | 2,155 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-002509 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vlad Coric Family Trust Disclosed balance after: 840,659 F1 · kind: Pursuant to an agreement and plan of merger, dated as of January 7, 2024, common shares of the Issuer were issued to the Reporting Person on March 8, 2024. The acquisition of the acquired company pursuant to the agreement and plan of merger and the issuance of common shares of the Issuer to the Reporting Person in connection therewith were approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to an agreement and plan of merger, dated as of January 7, 2024, common shares of the Issuer were issued to the Reporting Person on March 8, 2024. The acquisition of the acquired company pursuant to the agreement and plan of merger and the issuance of common shares of the Issuer to the Reporting Person in connection therewith were approved by the Board of the Issuer pursuant to Rule 16b-3. F3 · ownership.nature: These common shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2024 Filed Mar 8, 2024 23:35 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantCommon Shares | 2,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-002509 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,666,234 F1 · kind: Pursuant to an agreement and plan of merger, dated as of January 7, 2024, common shares of the Issuer were issued to the Reporting Person on March 8, 2024. The acquisition of the acquired company pursuant to the agreement and plan of merger and the issuance of common shares of the Issuer to the Reporting Person in connection therewith were approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to an agreement and plan of merger, dated as of January 7, 2024, common shares of the Issuer were issued to the Reporting Person on March 8, 2024. The acquisition of the acquired company pursuant to the agreement and plan of merger and the issuance of common shares of the Issuer to the Reporting Person in connection therewith were approved by the Board of the Issuer pursuant to Rule 16b-3. F2 · balance_after: This balance includes 305 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2023, and 1,336 shares that were acquired through the Biohaven Employee Share Purchase Plan on November 30, 2023. Read SEC document |
| January 08, 2024 Filed Jan 11, 2024 02:11 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantCommon Shares | 5,384 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-000426 · primarydocument.xml · nonDerivative · entry 3 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vladimir Coric Marital Trust Disclosed balance after: 404,827 F1 · kind: Pursuant to a merger transaction, consummated on January 8, 2024, common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to a merger transaction, consummated on January 8, 2024, common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F2 · ownership.nature: These common shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 08, 2024 Filed Jan 11, 2024 02:11 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantCommon Shares | 5,384 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-000426 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vlad Coric Family Trust Disclosed balance after: 838,504 F1 · kind: Pursuant to a merger transaction, consummated on January 8, 2024, common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to a merger transaction, consummated on January 8, 2024, common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F2 · ownership.nature: These common shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 08, 2024 Filed Jan 11, 2024 02:11 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantCommon Shares | 5,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-000426 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,662,431 F1 · kind: Pursuant to a merger transaction, consummated on January 8, 2024, common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to a merger transaction, consummated on January 8, 2024, common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:07 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 275,000 | $0.00 Strike: $41.93 | $0.00 |
DisclosureSEC source: 0001562180-24-000283 · primarydocument.xml · derivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Shares · 275,000 shares Expires 2034-01-02 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on January 2, 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| November 02, 2023 Filed Nov 7, 2023 01:34 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 225,000 | $0.00 Strike: $29.49 | $0.00 |
DisclosureSEC source: 0001562180-23-007579 · primarydocument.xml · derivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Shares · 225,000 shares Expires 2033-11-02 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on November 2, 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 11:17 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Shares | 113,637 | $22.00 | $2,500,014.00 |
DisclosureSEC source: 0001562180-23-007246 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,657,031 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 11:17 UTC | Biohaven Ltd. BHVN · Entity 4379 | PurchaseCommon Share | 340,908 | $22.00 | $7,499,976.00 |
DisclosureSEC source: 0001562180-23-007246 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vladimir Coric Family Trust Disclosed balance after: 833,120 F1 · shares: Represents common shares acquired in an underwritten public offering. F2 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.